Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Regeneron Provides Updates on Phase 3 Libtayo® (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Regeneron (NASDAQ: REGN) Delayed: 784.85 -4.6 (0.58%)
Previous Close $789.45    52 Week High $592.36 
Open $787.34    52 Week Low $325.35 
Day High $794.73    P/E 206.00 
Day Low $779.65    EPS $3.81 
Volume 2,473,425